Coeptis Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.95
- Today's High:
- $1.07
- Open Price:
- $0.95
- 52W Low:
- $1.03
- 52W High:
- $12.13
- Prev. Close:
- $0.985
- Volume:
- 97942
Company Statistics
- Market Cap.:
- $36.84 million
- Book Value:
- 0.061
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $75000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -245.55%
- Return on Equity TTM:
- -1449.7%
Company Profile
Coeptis Therapeutics Inc had its IPO on 2020-12-17 under the ticker symbol COEP.
The company operates in the Healthcare sector and Biotechnology industry. Coeptis Therapeutics Inc has a staff strength of 4 employees.
Stock update
Shares of Coeptis Therapeutics Inc opened at $0.95 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.95 - $1.07, and closed at $0.95.
This is a -3.55% slip from the previous day's closing price.
A total volume of 97,942 shares were traded at the close of the day’s session.
In the last one week, shares of Coeptis Therapeutics Inc have slipped by -10.38%.
Coeptis Therapeutics Inc's Key Ratios
Coeptis Therapeutics Inc has a market cap of $36.84 million, indicating a price to book ratio of 17.4238 and a price to sales ratio of 45.681.
In the last 12-months Coeptis Therapeutics Inc’s revenue was $0 with a gross profit of $75000 and an EBITDA of $-23928664. The EBITDA ratio measures Coeptis Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Coeptis Therapeutics Inc’s operating margin was 0% while its return on assets stood at -245.55% with a return of equity of -1449.7%.
In Q1, Coeptis Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1563.7%.
Coeptis Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Coeptis Therapeutics Inc’s profitability.
Coeptis Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.0289. Its price to sales ratio in the trailing 12-months stood at 45.681.
Coeptis Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.94 million
- Total Liabilities
- $1.98 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Coeptis Therapeutics Inc ended 2024 with $5.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.94 million while shareholder equity stood at $1.29 million.
Coeptis Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $1.98 million in other current liabilities, 2094.00 in common stock, $-73607967.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.11 million and cash and short-term investments were $2.11 million. The company’s total short-term debt was $1,531,561 while long-term debt stood at $150000.00.
Coeptis Therapeutics Inc’s total current assets stands at $2.28 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $242453.00 and inventory worth $0.
In 2024, Coeptis Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Coeptis Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.95
- 52-Week High
- $12.13
- 52-Week Low
- $1.03
- Analyst Target Price
- $5
Coeptis Therapeutics Inc stock is currently trading at $0.95 per share. It touched a 52-week high of $12.13 and a 52-week low of $12.13. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $1.19 and 200-day moving average was $1.49 The short ratio stood at 1.71 indicating a short percent outstanding of 0%.
Around 5211% of the company’s stock are held by insiders while 1949.9% are held by institutions.
Frequently Asked Questions About Coeptis Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn’s disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.